Press Releases (-) Any 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2021 February 1, 2021 argenx announces launch of proposed global offering February 1, 2021 argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis January 8, 2021 argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline January 6, 2021 argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China January 4, 2021 argenx to Present at 39th Annual J.P. Morgan Healthcare Conference 2020 November 23, 2020 argenx Enters Into Agreement To Acquire Priority Review Voucher November 17, 2020 argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience November 9, 2020 argenx to Participate in Upcoming Virtual Investor Conferences October 22, 2020 argenx Reports Third Quarter 2020 Financial Results and Provides Business Update October 15, 2020 argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 October 6, 2020 argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships October 5, 2020 argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
